Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid. METHODS: We conducted a double-blind, placebo-controlled, phase 3 trial involving patients with mild dementia due to Alzheimer's disease, defined as a Mini-Mental State Examination (MMSE) score of 20 to 26 (on a scale from 0 to 30, with higher scores indicating better cognition) and with amyloid deposition shown by means of florbetapir positron-emission tomography or Aβ1-42 measurements in cerebrospinal fluid. Patients were randomly assigned to receive solanezumab at a dose of 400 mg or placebo intravenously every 4 weeks for 76 weeks. The primary outcome was the change from baseline to week 80 in the score on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; scores range from 0 to 90, with higher scores indicating greater cognitive impairment). RESULTS: A total of 2129 patients were enrolled, of whom 1057 were assigned to receive solanezumab and 1072 to receive placebo. The mean change from baseline in the ADAS-cog14 score was 6.65 in the solanezumab group and 7.44 in the placebo group, with no significant between-group difference at week 80 (difference, -0.80; 95% confidence interval, -1.73 to 0.14; P=0.10). As a result of the failure to reach significance with regard to the primary outcome in the prespecified hierarchical analysis, the secondary outcomes were considered to be descriptive and are reported without significance testing. The change from baseline in the MMSE score was -3.17 in the solanezumab group and -3.66 in the placebo group. Adverse cerebral edema or effusion lesions that were observed on magnetic resonance imaging after randomization occurred in 1 patient in the solanezumab group and in 2 in the placebo group. CONCLUSIONS: Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline. (Funded by Eli Lilly; EXPEDITION3 ClinicalTrials.gov number, NCT01900665 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the expedition3 trial (NCT01900665), aimed at further validating the drug’s efficacy in patients with mild AD, the drug was declared unsuccessful in 2016, as it failed to meet its primary endpoints.457–459”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [459]
In the citing paper
“In three completed phase 3 clinical trials (EXPEDITION, EXPEDITION2, EXPEDITION3), solanezumab did not significantly reduce the decline in cognition or function (e.g., activities of daily living and community involvement) in patients who had received a clinical diagnosis of mild-to-moderate AD [79].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [79]
In the citing paper
“Florbetapir PET analysis did not show a reduction in brain amyloid deposits with solanezumab [45, 46].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [46]
In the citing paper
“anti-Aβ mAbs that predominantly bind to monomeric Aβ do not mediate substantial removal of plaque and lack clinical efficacy”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [42]
In the citing paper
“A third phase 3 trial in mild AD also failed to demonstrate a significant benefit on the primary endpoint (Honig et al., 2018).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Honig et al., 2018
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Measurement of Functional Activities in Older Adults in the Community
Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H., Chance, J. M., & Filos, S. (1982) · Journal of Gerontology · doi:10.1093/geronj/37.3.323 · Cited by 2,972
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Cited by
Items 901–999 of 999
Disease Modification in Alzheimer’s Disease: Current Thinking
Liu‐Seifert, H., Schumi, J., Miao, X., Tian, Y., Rabbia, M. A., Andersen, S. W., Wilson, S., Li, W., & Entsuah, R. (2019) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479019841894 · Cited by 1
Self-citationAbdullah, L. I., Crawford, F., Langlois, H., Tsolaki, M., Börjesson‐Hanson, A., Rikkert, M. G. M. O., Pasquier, F., Wallin, A., Kennelly, S., Hendrix, S. B., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/345652 · Cited by 1
“stage AD subjects demonstrated benefit, such as Solanezumab (5, 8, 25), aducanumab (6) and LipiDiDiet trials (7).”
BackgroundInfluentialArterial System: A Missing Link in the Pathophysiology of Dementia?
Levy, B. I., Merkulova‐Rainon, T., & Kubis, N. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11829 · Cited by 1
Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases)
Pedrini, S., Morici, M., & Martins, R. N. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch14 · Cited by 2
Qu, C. F., Li, Q., Su, Z., Ip, S., Yuan, Q., Xie, Y., Xu, Q., Yang, W., Huang, Y., Xian, Y., et al. (2020) · doi:10.21203/rs.3.rs-41611/v1 · Cited by 1
Qi, W., Long, Y., Li, Z., Zhao, Z., Shi, J., Xie, W., Wang, L., Tan, Y., Zhou, T., Jiang, P., et al. (2024) · eLife · doi:10.7554/elife.99462.1 · Cited by 1
Strategies for Neuroprotection in Alzheimer's Disease
Jasutkar, H. G. (2025) · Wiley eBooks · doi:10.1002/9783527844678.ch5 · Cited by 1
Macaulay, O., Servilla, M., Arredondo, D., Virupakshappa, K., Hu, Y., Tafoya, L. E., Zhang, Y., & Sahu, A. D. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.24.614782 · Cited by 3
Solanezumab auch bei milder Alzheimer-Demenz wirkungslos
Lieb, K. (2018) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-018-2563-4
Müller, T. H. (2018) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-018-2584-z
Blank, R. H. (2018) · Springer eBooks · doi:10.1007/978-981-13-0656-3_3
Expected Role of the Rehabilitation Doctors for Treatment of Dementia
Mihara, M. (2018) · リハビリテーション医学 : 日本リハビリテーション医学会誌 · doi:10.2490/jjrmc.55.634
Que penser de l’approche médicamenteuse préventive de la maladie d’Alzheimer ?
Dubois, B., Epelbaum, S., & Villain, N. (2018) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30315-2
Adhikari, R. (2019) · Digital Commons - Michigan Tech (Michigan Technological University) · doi:10.37099/mtu.dc.etdr/891 · Cited by 1
Corvol, J. (2019) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2019.11.012 · Cited by 3
Hoffnungen und Rückschläge in der Alzheimer-Therapie
Jessen, F. (2019) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-019-2302-9
Traitement de la maladie d’Alzheimer : une lueur au bout du tunnel ?
Pariente, J., Rafiq, M., Bénaiteau, M., Gouilly, D., Pomies, E., Jasse, L., Drif, A., Calvas, F., Payoux, P., Rascol, O., et al. (2019) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2019.12.003
Kamei, N., & Takeda‐Morishita, M. (2019) · Drug Delivery System · doi:10.2745/dds.34.360 · Cited by 1
Clinical and biomarker changes in sporadic Alzheimer’s diseasePreprint
Zhuo, J., Zhang, Y., Liu, B., Liu, Y., Zhou, X. A., Bartlett, P. F., Jiang, T., & Initiative, T. A. D. N. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.08.084293
Alzheimer’s disease pathogenesis and risk factors
Gerulytė, A., & Strumylaitė, L. (2019) · Neurologijos seminarai · doi:10.29014/ns.2019.25 · Cited by 1
Synapsin-caveolin-1 mitigates cognitive deficits and neurodegeneration in Alzheimer’s disease micePreprint
Wang, S., Leem, J. S., Podvin, S., HOOK, V. Y. H., Kleschevnikov, N., Savchenko, P., Dhanani, M., Zhou, K., Kelly, I. C., Zhang, T., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.24.220129
“Unfortunately, efforts to combat the disease have been hindered by the growing list of failed clinical trials with interventions focused on reducing amyloid-related pathology, thus causing many to reconsider the amyloid hypothesis as the primary cause of AD(Doody et al., 2014; Hardy & Higgins, 1992; Honig et al., 2018…”
BackgroundMuthuraman, A., Ramesh, M., & Kumar, T. V. R. (2020) · Springer eBooks · doi:10.1007/978-981-15-5167-3_6
Spontaneous Breakdown of Long‐Lived Proteins in Aging and Their Implications in Disease
Friedrich, M. G. (2021) · Wiley eBooks · doi:10.1002/9783527826759.ch4 · Cited by 1
Beyond the budget silo approach: estimating health system sustainability for future dementia drugs
Gozzo, L., Benfatto, G., Giorgianni, F., Sultana, J., Rossi, E. A. L., Longo, L., Mansueto, S., Vitale, D. C., Savoca, C., Caraci, F., et al. (2020) · doi:10.36118/pharmadvances.03.2020.01
Clinical Validation of Neuronal Pentraxin Receptor as a Candidate Biomarker for Alzheimer’s Disease
Lim, B. (2020) · TSpace (University of Toronto)
The Hypothesis That Refuses to Die
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.012
Baloyannis, S. J. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98436
Spatial Extent of Amyloid-β Levels and Associations with Alzheimer’s Disease BiomarkersPreprint
Ozlen, H., Binette, A. P., Köbe, T., Meyer, P., Breitner, J. C. S., Poirier, J., & Villeneuve, S. (2021) · Research Square · doi:10.21203/rs.3.rs-711524/v1
Martone, R. L., & Shook, J. R. (2021) · AJOB Neuroscience · doi:10.1080/21507740.2021.1941399
“(Honig et al. 2018).”
Handling Intercurrent Events Through Hypothetical Strategy in Delayed-Start Designs
Wei, Y., Li, W., Liu, F., Liu, G. F., & Entsuah, R. (2021) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2021.2008483
Alternance et cohabitation se succèdent
Joseph, H. (2012) · Publications Docs-en-stock.com
Exploring the Efficacy of Anti-amyloid-β Therapeutics in Treating Alzheimer Disease
Downey, C. (2022) · Youth STEM Matters · doi:10.51892/ysm.1.202201
Mast Cells and their Role in Health and Disease
Faustino, A., & Oliveira, P. A. (2022) · Nova Science Publishers eBooks · doi:10.52305/gpjw5150
Quelles perspectives de traitements curatifs à court et à long terme pour la maladie d’Alzheimer ?
Delrieu, J., & Ousset, P. (2022) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2022.01.012 · Cited by 2
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.020
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.013
Disease “Redefinition”: A Tough Pill to Swallow
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.005
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.008
The Shaky Six and the “Second Reality”
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.003
Predictions for the 2020s and Beyond
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.017
The Scientific and Lay Narratives
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.014
Note Added at Press Time – Reviving LOF
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.019
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.001
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.015
Epilogue: “When Will We Have a Cure for Parkinson’s Disease?”
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.018
The Moonshot: Population-Based Studies of Aging
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.016
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.002
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.010
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.004
Biomarkers: The Promise and the Fallacy
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.009
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.007
Drug development and Alzheimer's disease
Delrieu, J., & Vellas, B. J. (2022) · Wiley eBooks · doi:10.1002/9781119484288.ch68
Self-citationValley of Death and the Role of Venture Philanthropy in Alzheimer’s Disease Drug Development
Friedman, L. G., Owen, M., Travaglia, A., & Fillit, H. M. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759.043
Reply to A Letter Concerning “Aducanumab: What About the Patient?”
Petersen, R. C. (2022) · Annals of Neurology · doi:10.1002/ana.26344
“Since cdk5 is an important tau kinase, this raises the possibility that an important contribution to the causation of AD is a combination of Aβ oligomer toxicity and Aβ fibril (plaque) toxicity, and that both forms of Aβ toxicity must be mitigated in order to preserve synaptic integrity, the best correlate for cogniti…”
BackgroundAlzheimer-Erkrankung – welche Substanzen befinden sich derzeit in Phase-III-Studien?
Häger, K. (2022) · Der Nervenarzt · doi:10.1007/s00115-022-01275-5
dos Santos, G. A. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-94383-7_1 · Cited by 1
Minchao, H. E., & Yuhong, W. A. N. G. (2022) · Research Square · doi:10.21203/rs.3.rs-1429156/v1
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.021
Phase 3 trial fails to show benefit of solanezumab in mild Alzheimer's disease
(2018) · The Brown University Psychopharmacology Update · doi:10.1002/pu.30330
Meta-Analysis of Natural vs Pharmaceutical Interventions for Alzheimer's Disease
Vrublevskaya, T. (2021) · San José State University ScholarWorks (San Jose State University) · doi:10.31979/etd.b494-dcd5
Ashford, J. W. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734280398.793553881
Li, F., Amith, M. “., Xiong, G. Y., Du, J., Xiang, Y., Rao, G., Pham, H. A., & Tao, C. (2020) · doi:10.2196/preprints.17944
Plasma miRNAs as Biomarkers for Amnestic Mild Cognitive Impairment and Modulation on BACE1Preprint
He, H., Yang, H., Zhang, W., Xie, Z., Zhang, M., Xu, H., Liu, Y., An, N., Hong, B., Yan, F., et al. (2020) · doi:10.21203/rs.3.rs-35767/v1
Novel perspectives from existing data on early Alzheimer’s disease pathology and dementia care use
Janssen, O. (2022) · Research Publications (Maastricht University) · doi:10.26481/dis.20220617oj
Risk Factors and Non-Pharmacological Prevention of Dementia
D’Hooge, R., der Jeugd, A. V., Engelborghs, S., Waldorff, F. B., & Vandenbulcke, M. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108918954.009
Antiamyloid therapy of Alzheimer’s disease: origins, current state and prospects of development
Vorobev, S. V., Emelin, А. Y., Yanishevskij, S. N., Kostina, E. V., & Galaeva, A. A. (2022) · Neurology Bulletin · doi:10.17816/nb108278
Plasma Proteomics To Identify the Biomarkers and Pathogenesis of Mild Cognitive ImpairmentPreprint
Hou, Z., Sun, A., Song, X., Liu, S., Hu, X., Luan, Y., Guan, H., He, C., Sun, Y., & Chen, J. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4182279
Henniges, P. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9694
Can motional dynamics account for the cytotoxicity of beta amyloid oligomers?Preprint
Yeh, C., Chang, H., Hsu, W.-H., Huang, S., Wu, M., Tu, L., Lee, M., & Chan, J. C. C. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.04.539338
(2021) · Romanian Journal of Psychiatry & Psychotherapy · doi:10.37897/rjpp.2021.1.3
Noninfectious Disease Vaccines
Speiser, D. E., El-Turabi, A., & Bachmann, M. F. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00042-6
Mechanisms of Thai medicinal plant extracts on the attenuation of glutamate-mediated neurotoxicity
Prasansuklab, A. (2017) · Chula Digiverse · doi:10.58837/chula.the.2017.156
Repercussion of Primary Nucleation Pathway: Dementia and Cognitive Impairment
Singh, A., Ansari, V. A., Mahmood, T., Ahsan, F., & Maheshwari, S. (2023) · Current Aging Science · doi:10.2174/0118746098243327231117113748
Alzheimer’s Dementia or Alzheimer’s Disease: What’s the Difference and Why Should We Care?
Gibbs, D. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009430067.004
An overview on Alzheimer’s disease, diagnosis and treatment approach
Nivetha, S. R., Shivani, K., Vigneshwaran, R., Prasanna, G. L., & Veeramani, M. (2023) · International Journal of Allied Medical Sciences and Clinical Research · doi:10.61096/ijamscr.v11.iss4.2023.379-391 · Cited by 1
TERAPIAS EMERGENTES NA DOENÇA DE ALZHEIMER: RUMO A UMA ABORDAGEM MAIS EFICAZ E PERSONALIZADA
Ferreira, T. G., Osório, L. P. L. D. C., da Silva, L. B., Néto, B. A. C. S., Pena, A. C. V., Alves, T. F., Ferraz, C. F., da Silva, Í. D., de Matos, M. G. B., & de Oliveira, J. G. R. (2024) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v10i3.13220 · Cited by 1
Habekost, M., Poulsen, E. T., Enghild, J. J., Denham, M., Jørgensen, A. L., & Qvist, P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.21.585176
Hugging it out: Targeting oxytocin in alzheimer’s disease
Koulousakis, P. (2024) · Research Publications (Maastricht University) · doi:10.26481/dis.20240523pk
Introduction to the Special Issue on the A4 Study
Aisen, P. S. S., & Sperling, R. A. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.118
Die Behandlung der Alzheimer-Krankheit mit Amyloid-Antikörpern
Adler, G. (2024) · Nervenheilkunde · doi:10.1055/a-2318-5718
Chapter 43. Agents for Neurocognitive Disorders
Ayers, G. M., & Brown, F. W. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as43
Therapeutic antibodies as a Wright Brothers' airplane: Clinical proof-of-concept
Saido, T. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28979-8.00015-2
Paterno, G., Moore, B. D., Bell, B. M., Gorion, K.-M. M., Ran, Y., Prokop, S., Golde, T. E., & Giasson, B. I. (2024) · Antibodies · doi:10.3390/antib13030068
A Machine Learning Approach to Predict Cognitive Decline in Alzheimer’s Disease Clinical TrialsPreprint
Nallapu, B. T., Petersen, K. K., Qian, T., Demirsoy, İ., Ghanbarian, E., Davatzikos, C. A., Lipton, R. B., Ezzati, A., & Initiative, A. D. N. (2024) · medRxiv · doi:10.1101/2024.09.03.24312481
Pharmacotherapy of Alzheimer's disease: A thorny road to success
Ibrahim, N. H., Kumar, J., & Mohamed, W. M. Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15702-8.00027-0
Murshid, N. M., Sahardi, N. F. N. M., & Makpol, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010241 · Cited by 1
Immunotherapy for Alzheimer's disease: advances in adaptive immunity
Zhi, T. (2025) · New discovery. · doi:10.61958/ndfs3904
Shtrahman, M., Parylak, S., Toda, T., & Gage, F. H. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780190065324.003.0009
Bouvenot, G. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.02.009 · Cited by 2
Qi, W., Long, Y., Li, Z., Zhao, Z., Shi, J., Xie, W., Wang, L., Tan, Y., Zhou, T., Liang, M., et al. (2025) · eLife · doi:10.7554/elife.99462.2
REVOLUTIONIZING ALZHEIMER’S THERAPEUTICS: FROM MICROTECHNOLOGIES TO AI-DRIVEN INNOVATIONS
Lahiri, A., Balamuralidhara, V., Manohar, S. K., & R., A. A. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i3.53726
“The primary outcomes of the trial and its impact on cognitive decline did not show significant differences among the administered doses [180, 181].”
«Failures» and current developments in the search for a cure for Alzheimer disease
Ganzgorn, E. V., Peglivanov, S. S., Pogrebnyak, A. V., Stumaitis, T. S., & Kiev, N. H. ‐. (2025) · Glavvrač (Chief Medical Officer) · doi:10.33920/med-03-2505-06
Biomarkers as Outcome Measures in Clinical Trials of Alzheimer Disease
Tarawneh, R. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_15
New Biomarkers and Biological Therapies in Alzheimer’s Disease
Balcerzak, W. (2025) · Biuletyn Głównej Biblioteki Lekarskiej · doi:10.2478/bgbl-2025-0012
Hu, H. B., Bryś, M., Ruberg, S. J., & Qu, Y. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-025-00843-6
“We applied the aforementioned estimand endpoints to the EXPEDITION-3 study [15], a double-blinded placebo-controlled phase 3 clinical trial of solanezumab for patients with mild dementia due to Alzheimer’s disease.”
Wang, X., Han, Y., Liu, Y., Tang, S., & Hsu, J. C. (2025) · Statistical Analysis and Data Mining The ASA Data Science Journal · doi:10.1002/sam.70039
The Evolving Landscape of Amyloid Research
Bonilauri, B. (2025) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.70048
Prospects for the Treatment of Alzheimer’s Disease
Васильевна, В. Н., Novikov, D. K., Vekhova, K. A., Zhuk, A. M., Klimanovich, D. L., Isaikin, A. I., & Zakharov, V. V. (2025) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-025-01882-0
“Bapineuzumab showed no difference from placebo in terms of cognitive function in trial participants, but it reduced A β accumulation [25].”
Atkins, A. S., Marquis, S., Creel, K., Meunier, J., Cano, S., Delbecque, L., Shan, M., & Wessels, A. M. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70656
“9–12 Most recently, the iADRS was used to demonstrate clinical efficacy of donanemab, 13 making it the second of two primary endpoints used in successful FDA submissions for disease modifying treatments (DMTs) for early symptomatic AD, the first being the CDR-SB.”
Metadata
- Authors
- Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., Case, M., Dean, R. A., Hake, A., Sundell, K., Poole Hoffmann, V., Carlson, C., Khanna, R., Mintun, M., DeMattos, R., Selzler, K. J., & Siemers, E.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- From the Department of Neurology and Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); Gérontopôle, Centre Hospitalier Universitaire Toulouse, Unité Mixte de Recherche INSERM Unité 1027 Université Toulouse III–Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC — both in Australia (M.W.); Fundació ACE, Alzheimer Research...
- Western University (CA)
- Karolinska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-01-25
- Volume
- 378
- Issue
- 4
- Pages
- 321-330
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2787612390
- Cited by
- 1,049
- References
- 27
- Citations by year
- 2026: 48 · 2025: 93 · 2024: 121 · 2023: 123 · 2022: 136 · 2021: 129 · 2020: 169 · 2019: 136 · 2018: 91
- FWCI
- 90.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- IUScholarWorks (Indiana University) (submittedVersion)
- Publisher
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- solanezumab, Alzheimer's disease, mild dementia, amyloid-beta, humanized monoclonal antibody, amyloid-beta clearance, cognitive decline, florbetapir PET, cerebral edema, treatment efficacy, amyloid plaques, neurofibrillary tangles
- MeSH terms
- Mental Status and Dementia Tests, Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Double-Blind Method, Female, Humans, Immunotherapy, Infusions, Intravenous, Male, Middle Aged, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, Treatment Failure, Positron-Emission Tomography, Plaque, Amyloid, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.